PUBLICATION
Marine Biodiscovery Goes Deeper: Using In Vivo Bioassays Based on Model Organisms to Identify Biomedically Relevant Marine Metabolites
- Authors
- West, K.H., Crawford, A.D.
- ID
- ZDB-PUB-160519-6
- Date
- 2016
- Source
- Planta Medica 82(9-10): 754-60 (Review)
- Registered Authors
- Crawford, Alexander
- Keywords
- Caenorhabditis elegans, Drosophila melanogaster, Danio rerio, in vivo bioassay, marine biodiscovery, zebrafish, bioassay-guided fractionation
- MeSH Terms
-
- Animals
- Aquatic Organisms*
- Biological Assay/methods
- Biological Products*
- Caenorhabditis elegans
- Drosophila
- Drug Discovery*/methods
- Humans
- Models, Biological
- Zebrafish
- PubMed
- 27191583 Full text @ Planta Med.
Citation
West, K.H., Crawford, A.D. (2016) Marine Biodiscovery Goes Deeper: Using In Vivo Bioassays Based on Model Organisms to Identify Biomedically Relevant Marine Metabolites. Planta Medica. 82(9-10):754-60.
Abstract
Secondary metabolites from marine organisms are structurally diverse small molecules with high levels of bioactivity, and represent an underutilized resource for modern drug discovery. To facilitate the identification of drug-like marine metabolites, the significant potential of in vivo models of human disease - in particular those suitable for medium-throughput screening and bioassay-guided fractionation - should be explored in future marine biodiscovery efforts. Here, we explore the advantages of Caenorhabditis elegans, Drosophila, and zebrafish bioassays for marine biodiscovery, and review recent progress in using these in vivo models to identify bioactive marine metabolites.
Genes / Markers
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Orthology
Engineered Foreign Genes
Mapping